ZYBT (Jilin Zhengye Biotechnology) יתרות המזומנים של החברה

Zhengye Biotechnology (ZYBT) maintains a strong position in the Chinese veterinary drug market driven by its patents. The volume of cash reserves confirms this stability, with the indicator reaching the level of 0.01. Liquidity is increasing due to the low cost of mass-produced vaccines following the payback period of the laboratories. Capital security is further supported by the implementation of thermostable transportation, which eliminates losses during product delivery.
פילוחי נתונים אנליטיים מרוכזים עבור Zhengye Biotechnology Co., Ltd. (ZYBT)

For Zhengye Biotechnology (ZYBT), the volume of liquid reserves determines the capacity to maintain the production of veterinary vaccines and test systems in the domestic market. The current value of 0.01 reflects the actual balance of funds available to cover operating expenses without incurring external debt. By analyzing the history of cash flow changes, an investor can identify the risk of a liquidity gap or inefficiencies in capital management. A stable liquidity balance confirms the company's financial stability during its preparation for export expansion.